Status:
UNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders
Lead Sponsor:
Assiut University
Conditions:
Lymphoproliferative Disorders
Eligibility:
All Genders
Brief Summary
1. To study the expression pattern of CD19(cluster of differentiation antigen19) complex in lymphoproliferative disorders and its diagnostic value. 2. To investigate the biological significance of CD1...
Detailed Description
Lymphoproliferative disorders (LPD)comprise a heterogeneous group of diseases characterized by uncontrolled production of lymphocytes that cause monoclonal lymphocytosis, lymphadenopathy and bone marr...
Eligibility Criteria
Inclusion
- Patients with acute lymphoproliferative disorders.
- Patients with chronic lymphoproliferative disorders
Exclusion
- patients with non lymphoid disorders.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2023
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT04734470
Start Date
March 1 2021
End Date
April 1 2023
Last Update
February 4 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.